PDK LABS INC
10-Q, EX-27, 2000-07-14
PHARMACEUTICAL PREPARATIONS
Previous: PDK LABS INC, 10-Q, 2000-07-14
Next: MILESTONE SCIENTIFIC INC/NJ, AW, 2000-07-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
The schedule contains summary financial information extracted from the financial
statements and is qualified in its entirety by reference to such financial
statements.
</LEGEND>


<MULTIPLIER>                                   1,000


<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              NOV-30-2000
<PERIOD-END>                                   MAY-31-2000
<CASH>                                               1,026
<SECURITIES>                                         3,407
<RECEIVABLES>                                        9,651
<ALLOWANCES>                                            54
<INVENTORY>                                          8,943
<CURRENT-ASSETS>                                    26,712
<PP&E>                                              11,992
<DEPRECIATION>                                       8,704
<TOTAL-ASSETS>                                      34,264
<CURRENT-LIABILITIES>                                2,482
<BONDS>                                              1,622
                                    0
                                              5
<COMMON>                                                38
<OTHER-SE>                                          29,274
<TOTAL-LIABILITY-AND-EQUITY>                        34,264
<SALES>                                             24,076
<TOTAL-REVENUES>                                    24,076
<CGS>                                               16,944
<TOTAL-COSTS>                                       16,944
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                     125
<INCOME-PRETAX>                                      1,510
<INCOME-TAX>                                           471
<INCOME-CONTINUING>                                  1,053
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                         1,053
<EPS-BASIC>                                            .41
<EPS-DILUTED>                                          .41


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission